Innovation in medicines

  • Email
  • Help

One of the European Medicines Agency's (EMA) strategic goals is to promote development of innovative veterinary medicines and new technologies. Technologies that are new to veterinary medicine present particular challenges due to a lack of regulatory guidance and, in some cases, the fact that the existing regulatory framework does not specifically cater for them.

EMA's Committee for Medicinal Products for Veterinary Use has established the Ad Hoc Expert Group on Veterinary Novel Therapies (ADVENT) to provide guidance on the requirements for authorisation of novel veterinary therapies.

For further information on innovation in medicines, including information on the Innovation Task Force (ITF) and how to request an ITF briefing meeting, please refer to the content in the human regulatory section:


How helpful is this page?

Average rating:

 Based on 0 ratings

Add your rating:

See all ratings
0 ratings
0 ratings
0 ratings
0 ratings
0 ratings

Tell us more